Local pain during REBIF injection is not due to acidic pH [4]

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 7, 2004, Pages 1078-

  Buttmann, M ^a   Goebeler, M ^a   Rieckmann, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BETA INTERFERON; PLACEBO;

CHEMICAL COMPOSITION; DRUG FORMULATION; HUMAN; INJECTION SITE; INSTRUMENT STERILIZATION; LETTER; MEDICAL ASSESSMENT; PAIN; PH; PRESSURE; PRIORITY JOURNAL; RECIPIENT; SENSATION; SKIN BIOPSY;

EID: 3042840184     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.025114     Document Type: Letter

References (3)

1. PRISMS study group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
2. SPECTRIMS study group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504.
3. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 1998;357:156-82.